Evidence map›Paper›PMID 33313389›Full record

ArticleACS biomaterials science & engineering2020

Ferritin Nanocage Conjugated Hybrid Hydrogel for Tissue Engineering and Drug Delivery Applications.

Roya Samanipour, Ting Wang, Moritz Werb, Hamed Hassannezhad, Juan Manuel Ledesma Rangel, Mina Hoorfar, Anwarul Hasan, Chang Kee Lee, Su Ryon Shin

Open access · greenAbstract read
In one paragraph

Article in ACS biomaterials science & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 6 countries.

Roya SamanipourDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
Ting WangDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
Moritz WerbDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
Hamed HassannezhadDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
Juan Manuel Ledesma RangelDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.
Mina HoorfarDepartment of Mechanical Engineering, School of Engineering, University of British Columbia, Kelowna V6T 1Z4, Canada.
Anwarul HasanDepartment of Mechanical and Industrial Engineering, College of Engineering, Qatar University, 2713 Doha, Qatar.ORCID 0000-0001-8380-2233
Chang Kee LeeKorea Packaging Center, Korea Institute of Industrial Technology, Bucheon 31056, Republic of Korea.
Su Ryon ShinDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-0864-6482
Brigham and Women's Hospital · USJiangsu University · CNKorea Institute of Industrial Technology · KRQatar University · QAUniversity of British Columbia · CA

Funding

Oxygen generating bioinks for 3D printed bone implantsR01AR074234 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON · 2018 to 2022
$1.9M
Microengineered scaffolds carrying patient-specific cells and growth factors for treatment of volumetric muscle lossR01AR073822 · NIAMS · UNIVERSITY OF NEBRASKA LINCOLN · PI TAMAYOL, ALI · 2018 to 2022
$1.8M
Programmable multimaterial bioprinting of 3D vascularized tissue constructsR21EB026824 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON · 2018 to 2020
$685k
NIAMS NIH HHS R01 AR073822NIAMS NIH HHS R01 AR074234NIBIB NIH HHS R21 EB026824
6 · The paper itself

Abstract

Hydrogels have recently been attractive in various drug delivery and tissue engineering applications because of their structural similarities to the natural extracellular matrix. Despite enormous advances in the application of hydrogels, poor mechanical properties and lack of control for the release of drugs and biomolecules act as major barriers for widespread clinical applications. To overcome these challenges, we developed both physically and covalently conjugated nanocage-laden hydrogels between the surface of the nanocage and a gelatin methacryloyl (GelMA) hydrogel matrix. Ferritin and its empty-core equivalent apoferritin were used as nanocages that could be easily incorporated into a GelMA hydrogel via physical bonding. To fabricate covalently conjugated nanocage-laden GelMA hydrogels, ferritin and apoferritin were chemically modified to present the methacryloyl groups, ferritin methacryloyl (FerMA) and apoferritin methacryloyl (ApoMA), respectively. The covalently conjugated FerMA- and ApoMA-GelMA hydrogels offered a better ability to tune mechanical properties compared with those prepared by direct dispersion of ferritin and apoferritin into GelMA hydrogels with physical bonding, without affecting their porosity or cell growth. Furthermore, the ability of the nanocage to release small chemical compounds was confirmed by performing a cumulative release test on fluorescein isothiocyanate (FITC) encapsulated apoferritin and ApoMA incorporated GelMA hydrogels by pH stimulus. Thus, the nanocage incorporated hydrogels have emerged as excellent materials for drug delivery and tissue engineering applications.

Indexed as

Drug Delivery SystemsHydrogelsTissue EngineeringBiocompatible MaterialsFerritinsTissue ScaffoldsBiocompatible MaterialsFerritinsHydrogelsapoferritindrug deliveryferritinhydrogelnanocagetissue engineering

Identifiers

PMID33313389
PMCPMC7725239
OpenAlexW2984291908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.